Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators

被引:134
|
作者
Maisel, WH [1 ]
Sweeney, MO [1 ]
Stevenson, WG [1 ]
Ellison, KE [1 ]
Epstein, LM [1 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Cardiac Arrhythmia Serv, Boston, MA 02115 USA
来源
关键词
D O I
10.1001/jama.286.7.793
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Unanticipated pacemaker and implantable cardioverter-defibrillator (ICD) generator malfunctions sometimes warrant recall by the US Food and Drug Administration (FDA). Despite increasingly frequent device implantation, pacemaker and ICD recalls and safety alerts (advisories) remain poorly characterized. Objectives To determine pacemaker and ICD generator advisory rates in the United States, to identify trends in these rates, and to examine their clinical and financial implications. Design and Setting Analysis of weekly FDA Enforcement Reports issued between January 1990 and December 2000 to identify all advisories involving pacemaker or ICD generators in the United States. Recalls and safety alerts involving lead malfunctions were not included. Main Outcome Measures Number of pacemakers and ICD generators in the United States subject to FDA recall or safety alert in 1990-2000; annual pacemaker and ICD advisory rates in the United States in 1990-2000; and estimated cost of device advisories. Results During the study period, 52 advisories (median [25th and 75th percentiles], 4 [4 and 7] per year) involving 408500 pacemakers and 114645 ICDs (523 145 total devices) were issued. Hardware malfunctions (35 advisories affecting 280641 devices) and computer errors (10 advisories affecting 216533 devices) accounted for 95 % of device recalls. Implantable cardioverter-clefibrillators were recalled more frequently than pacemakers (mean [SD], 16.4 [1.6] vs 6.7 [0.8] advisories per 100 person-years; P<.001). Between 1995 and 2000, the annual advisory rate increased for both pacemakers (P for trend <.001) and ICDs (P for trend =.02). An estimated 1.3 million device checks and analyses and 36187 device replacements resulted from the advisories and cost approximately $870 million. Conclusions Pacemaker and ICD recalls and safety alerts occur frequently, affect many patients, and appear to be increasing in number and rate. With the growing number of device implants and expanding indications for device therapy, the number of patients affected by device advisories will likely continue to increase.
引用
收藏
页码:793 / 799
页数:7
相关论文
共 50 条
  • [1] Implantable cardioverter-defibrillator FDA recalls and safety alerts: Prevalence and impact on patient mortality
    Kendig, AC
    Khan, M
    Tchou, PJ
    Martin, DO
    Natale, A
    Wilkoff, BL
    Burkhardt, JD
    Bhargava, M
    Chung, MK
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 20A - 20A
  • [2] Indications for Pacemakers, Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Devices
    Samii, Soraya M.
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2015, 99 (04) : 795 - +
  • [3] Safety of Outpatient Implantation of the Implantable Cardioverter-defibrillator
    Datino, Tomas
    Miracle Blanco, Angel
    Nunez Garcia, Alberto
    Gonzalez-Torrecilla, Esteban
    Atienza Fernandez, Felipe
    Arenal Maiz, Angel
    Hernandez-Hernandez, Jesus
    Avila Alonso, Pablo
    Eidelman, Gabriel
    Fernandez-Aviles, Francisco
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (07): : 579 - 584
  • [4] Efficacy and Safety of an Extravascular Implantable Cardioverter-Defibrillator
    Friedman, Paul
    Murgatroyd, Francis
    Boersma, Lucas V. A.
    Manlucu, Jaimie
    O'Donnell, David
    Knight, Bradley P.
    Clementy, Nicolas
    Leclercq, Christophe
    Amin, Anish
    Merkely, Bela P.
    Birgersdotter-Green, Ulrika M.
    Chan, Joseph Y. S.
    Biffi, Mauro
    Knops, Reinoud E.
    Engel, Greg
    Carvajal, Ignacio Munoz
    Epstein, Laurence M.
    Sagi, Venkata
    Johansen, Jens B.
    Sterlinski, M.
    Steinwender, Clemens
    Hounshell, Troy
    Abben, Richard
    Thompson, Amy E.
    Wiggenhorn, Christopher
    Willey, Sarah
    Crozier, Ian
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (14): : 1292 - 1302
  • [5] Efficacy and Safety of an Extravascular Implantable Cardioverter-Defibrillator
    Di Lellis, Maddalena Angela
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (04) : 148 - 148
  • [6] The implantable cardioverter-defibrillator
    Raj, SR
    Sheldon, RS
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2001, 44 (03) : 169 - 194
  • [7] The implantable cardioverter-defibrillator
    Groh, WJ
    Foreman, LD
    Zipes, DP
    [J]. AMERICAN FAMILY PHYSICIAN, 1998, 57 (02) : 310 - 312
  • [8] The implantable cardioverter-defibrillator
    Greene, HL
    [J]. CLINICAL CARDIOLOGY, 2000, 23 (05) : 315 - 326
  • [9] BEAM PROFILE DISTURBANCES FROM IMPLANTABLE PACEMAKERS OR IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR INTERACTIONS
    Gossman, Michael S.
    Nagra, Bipinpreet
    Graves-Calhoun, Alison
    Wilkinson, Jeffrey
    [J]. MEDICAL DOSIMETRY, 2011, 36 (04) : 358 - 364
  • [10] Recall Alerts in Implantable Cardioverter-Defibrillator Recipients: Implications for Patients and Physicians
    Schwartz, Jerome
    Blangy, Hugues
    Zinzius, Pierre Yves
    Freysz, Luc
    Aliot, Etienne
    Sadoul, Nicolas
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2011, 34 (01): : 96 - 103